Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
Active, not recruiting
TransThera Biosciences Co., Ltd
Phase 1
This is a first-in-human, phase I clinical research study with TT-00420, an investigational,
oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor
micro-environment, for the treatment of triple negative breast cancer (TNBC) and other
advanced solid tumors. The study consists of a dose escalation part followed by a MTD
expansion part.
Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
Active, not recruiting
TransThera Sciences (Nanjing), Inc.
Phase 1
This is a first-in-human, phase I clinical research study with TT-00420, an investigational,
oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor
micro-environment, for the treatment of triple negative breast cancer (TNBC) and other
advanced solid tumors. The study consists of a dose escalation part followed by a MTD
expansion part.
Relative Bioavailability Study and Food Effect Study of TT-00420 Capsule and Tablet Formulations in Healthy Volunteers
Completed
TransThera Biosciences Co., Ltd
Phase 1
This study is an open-label, 3-way crossover randomized study in adult healthy volunteers to
evaluate the relative bioavailability of TT-00420 tablet and capsule formulations and to
evaluate food effect on the pharmacokinetics of TT-00420 tablet.
Relative Bioavailability Study and Food Effect Study of TT-00420 Capsule and Tablet Formulations in Healthy Volunteers
Completed
TransThera Sciences (Nanjing), Inc.
Phase 1
This study is an open-label, 3-way crossover randomized study in adult healthy volunteers to
evaluate the relative bioavailability of TT-00420 tablet and capsule formulations and to
evaluate food effect on the pharmacokinetics of TT-00420 tablet.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
